Los Angeles-based NeuroSigma, a developer of medical devices aimed at treating epilepsy and depression, has filed for an IPO, saying that it is looking to raise up to $50M on the public markets. The company said it has applied to list on the NASDAQ Global Market as NSIG. The life sciences company said its IPO is being underwritten by Jeffries, BTIG, and Craig-Hallum Capital Group. The company is currently marketing a product in the EU, Canada, and Australia for the treatment of epilepsy. Neurosigma's biggest shareholder is Dr. Leon Ekchian, the company's CEO and President, with 30.48% of the company before the IPO.